Base rate computed from analyst-asserted responds_to: edges in the reverse direction (target-country → issuer-country) for prior issuer-actions on the same target. Modal type + lag percentiles only — not a model output. Treat as a historical anchor for sizing counter-response scenarios, not a forecast in itself.

Theme momentum

1themes this action belongs to

EU-China public-procurement market-access reciprocity cycle

0 filings in 90d

→ steady

The European Commission adopted Commission Implementing Regulation (EU) 2025/1197 on 19 June 2025, published in the Official Journal on 20 June 2025 and applicable from 30 June 2025. It imposes the EU's first-ever International Procurement Instrument (IPI) measure, excluding tenders submitted by economic operators originating in China from EU public procurement contracts for medical devices (CPV codes 33100000-1 to 33199000-1) valued at EUR 5,000,000 or more net of VAT. Even where a non-Chinese bidder wins, no more than 50% of the contract's value may be sourced from China-origin medical devices (IPI Article 8(1)). Contracting authorities may waive the measure only where solely Chinese bidders meet requirements or for overriding public-interest reasons (IPI Article 9(1)).

Analyst notesShow

Mechanism

This is the European Commission's first-ever invocation of the International Procurement Instrument (Regulation (EU) 2022/1031), adopted under IPI Articles 6(1) and 6(6)(b) after the Commission's investigation found China's public-procurement market for medical devices to be structurally closed to EU bidders (domestic-content targets ranging 25-100%, with 100% required across 137 device categories, per the Commission's own investigation cited in secondary reporting). The measure operates on two tracks simultaneously: outright exclusion of China-origin bidders above the EUR 5m threshold, and a 50% import-content cap on the China-origin share of contracts won by non-Chinese suppliers. Severity is set at 4 (quant basis) given the binding EUR 5m threshold, the 50% content cap, and the fact that this is a first-invocation precedent for a coercive-trade-instrument track the EU had held in reserve since 2022.

China's Ministry of Finance responded on 3 July 2025 with Caiku [2025] No. 19 (see 2025-07-03-china-mof-eu-medical-device-procurement-restriction), mirroring the EU's structure with a CNY 45m threshold, exclusion of non-locally-invested EU bidders, and a 50% EU-import content cap — filed under the eu-china-procurement-market-access-reciprocity theme alongside this action.

Downstream implications

Establishes a usable IPI precedent the Commission can extend to other

sectors (rail, wind turbines, medical imaging) where FSR/IPI investigations are active or prospective.

Triggered an immediate reciprocal Chinese measure within two weeks,

suggesting future IPI designations will draw fast tit-for-tat responses rather than negotiated settlement.

Chinese medical-device exporters (e.g., Mindray, United Imaging) lose

access to EU tenders above the EUR 5m threshold; EU medical-device makers with China manufacturing exposure face the mirrored CNY 45m exclusion.

Open questions

Will the Commission expand IPI product-category designations beyond

medical devices in 2026?

Does the EUR 5m / 50%-content-cap structure become the template for

future IPI actions, or was medical devices a one-off pilot sector?

Does this track merge with the broader EU FSR/TIB dispute chain, or stay

procedurally separate as the theme note anticipates?

Sources

Primary: EUR-Lex — Commission Implementing Regulation (EU) 2025/1197 of 19 June 2025

Secondary: Baker McKenzie — EU Restricts Access of Chinese Medical Devices to the European Market

Loading…

Mechanism

Downstream implications

Establishes a usable IPI precedent the Commission can extend to other

sectors (rail, wind turbines, medical imaging) where FSR/IPI investigations are active or prospective.

Triggered an immediate reciprocal Chinese measure within two weeks,

suggesting future IPI designations will draw fast tit-for-tat responses rather than negotiated settlement.

Chinese medical-device exporters (e.g., Mindray, United Imaging) lose

access to EU tenders above the EUR 5m threshold; EU medical-device makers with China manufacturing exposure face the mirrored CNY 45m exclusion.

Open questions

Will the Commission expand IPI product-category designations beyond

medical devices in 2026?

Does the EUR 5m / 50%-content-cap structure become the template for

future IPI actions, or was medical devices a one-off pilot sector?

Does this track merge with the broader EU FSR/TIB dispute chain, or stay

procedurally separate as the theme note anticipates?